Datapoint: Pfizer Scores Another Hemophilia Nod

Pfizer has secured its second FDA approval for a hemophilia treatment within six months. The latest approval is for Hympavzi, a subcutaneous injection designed for patients aged 12 and older with hemophilia A or B who have not developed antibodies to previous treatments. This new therapy aims to reduce bleeding episodes and offers a more convenient alternative to traditional intravenous infusions. With its $795,600 wholesale acquisition cost (WAC), Hympavzi is positioned as a cost-effective option compared to other treatments on the market. Pfizer’s Beqvez, a gene therapy that treats hemophilia B, was approved in April. So far, the drug holds covered status for 32% of all insured lives under the medical benefit, often with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 10/14/24

0 Comments
© 2025 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 17

Datapoint: Michigan Awards Contracts for New Duals Program

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 16

Datapoint: CMS Releases 2025 Star Ratings

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 14

Datapoint: Clover Health Cleared in SEC Probe

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today